Discovery of PF-07054894, a Potent Squaramide-Based CCR6 Antagonist Displaying High CXCR2 Selectivity
Journal of Medicinal Chemistry · 2025
DOI: 10.1021/acs.jmedchem.5c01946 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2025. Verfasst von Mark E Schnute und 44 weiteren Autor:innen. Beteiligte Einrichtung: Medicine Design, Pfizer Inc, Cambridge, Massachusetts 02139, United States. Hauptthemen laut MEDLINE: Receptors, Interleukin-8B, Receptors, CCR6, Drug Discovery. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 63 Literaturangaben.
Abstract (Originalsprache)
The G protein-coupled receptor (GPCR) CCR6 mediates the migration of pathogenic immune cells to the site of inflammation in response to the chemokine CCL20. CCR6 is an attractive target for the treatment of chronic autoimmune disease as antagonism of the receptor is expected to block CCL20-mediated immune cell recruitment. High-throughput-screening identified a squaramide-based, allosteric antagonist of CCR6 that potently inhibited CCL20-mediated T cell chemotaxis, but it also inhibited CXCL1-mediated neutrophil chemotaxis through CXCR2 antagonism. Lead optimization achieved differentiation from CXCR2 through identification of a methyl substituent-dependent selectivity switch or “magic methyl for selectivity”. The mechanism for this effect is rooted in different antagonist-induced ligand–receptor behaviors, insurmountable for CCR6 and surmountable for CXCR2. Herein, we report the discovery and preclinical evaluation of the CCR6 antagonist PF-07054894 (18l) which has advanced to clinical trials as a first in class approach targeting the receptor.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Medicine Design, Pfizer Inc, Cambridge, Massachusetts 02139, United States.
- Medicine Design, Pfizer Inc, Groton, Connecticut 06340, United States.
- Inflammation and Immunology Research, Pfizer Inc, Cambridge, Massachusetts 02139, United States.
- Sosei Heptares, Steinmetz Building, Granta Park, Great Abington, Cambridge CB21 6DG, United Kingdom.
- Drug Product Design, Pfizer Inc, Cambridge, Massachusetts 02139, United States.
ORCID-Profile: Mark E Schnute, Huixian Wu, John I Trujillo, Scott W Bagley, Gary M Chinigo, Chulho Choi, Andrew Flick, Brian S Gerstenberger, Daniel W Kung, James J Mousseau, Arjun Narayanan, Michael J Primiano
Zitieren
APA
Schnute, M. E., Wu, H., Trujillo, J. I., Li, W., Wasilko, D. J., Alley, J., Arnold, E. P., Bagley, S. W., Berstein, G., Blakemore, D. C., Bundesmann, M. W., Chinigo, G. M., Choi, C., Cooke, R., Crouse, K., Dermenci, A., Dickinson, T., Flick, A., Frisbie, R. K., …, & Thorarensen, A. (2025). Discovery of PF-07054894, a Potent Squaramide-Based CCR6 Antagonist Displaying High CXCR2 Selectivity. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.5c01946
Vancouver
Schnute ME, Wu H, Trujillo JI, Li W, Wasilko DJ, Alley J, et al. Discovery of PF-07054894, a Potent Squaramide-Based CCR6 Antagonist Displaying High CXCR2 Selectivity. Journal of Medicinal Chemistry. 2025. doi:10.1021/acs.jmedchem.5c01946
BibTeX
@article{Schnute2025,
author = {Schnute, Mark E and Wu, Huixian and Trujillo, John I and Li, Wei and Wasilko, David Jonathan and Alley, Jennifer and Arnold, Eric P and Bagley, Scott W and Berstein, Gabriel and Blakemore, David C and Bundesmann, Mark W and Chinigo, Gary M and Choi, Chulho and Cooke, Robert and Crouse, Kimberly and Dermenci, Alpay and Dickinson, Theresa and Flick, Andrew and Frisbie, Richard K and Garcia-Irizarry, Carmen and Gerstenberger, Brian S and Hepworth, David and Kaila, Neelu and Kung, Daniel W and Lamb, Daniel and Lavergne, Sophie Y and Limburg, David C and Liu, Shenping and Lombardo, Vincent M and Mondal, Prolay K and Mousseau, James J and Narayanan, Arjun and Niljianskul, Nootaree and Nuhant, Philippe and Pan, Senliang and Primiano, Michael J and Rappas, Mathieu and Schmitt, Daniel C and Steyn, Stefanus J and Unwalla, Ray and Vasa, Dipy and Vazquez, Michael L and Vincent, Fabien and Yang, Xiaojing and Thorarensen, Atli},
title = {Discovery of PF-07054894, a Potent Squaramide-Based CCR6 Antagonist Displaying High CXCR2 Selectivity},
journal = {Journal of Medicinal Chemistry},
year = {2025},
doi = {10.1021/acs.jmedchem.5c01946}
}
EUVIMED